Clinical Efficacy and Adverse Reactions of Antipsychotic Treatment
Predictive Models of Clinical Efficacy and Adverse Reactions of Antipsychotic Treatment
The goal of this clinical trial is to explore the potential of metformin in managing olanzapine-induced metabolic disturbance and hyperprolactinemia in patients with schizophrenia. The main questions it aims to answer are:
- The effect of metformin on olanzapine-induced metabolic disturbance
- The effect of metformin on olanzapine-induced hyperprolactinemia
Participants will receive metformin 1500 mg/day for 8 weeks and assessments every 2 weeks.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Taipei, Taiwan, 116
- Taipei Medical University-Wan Fang Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- aged between 18 and 60 years
- diagnosed with schizophrenia under the Diagnostic and Statistical Manual of Mental Disorders-fourth edition criteria
- had been consistently treated with a stable dose of olanzapine for a minimum of three months
Exclusion Criteria:
- Exclusion criteria encompassed any mental disorder other than schizophrenia, ongoing substance abuse, and medical conditions that could interfere with glucoregulatory and endocrine assessment such as diabetes mellitus and other endocrine disorders. Additionally, severe cardiovascular, hepatic, or renal diseases, malignancy, epilepsy, and pregnancy were also reasons for exclusion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: metformin intervention
All participants were administered 1500 mg/day of metformin for eight weeks.
|
All participants were administered 1500 mg/day of metformin for eight weeks.
The trial design is single-group with no masking.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Glucose level
Time Frame: 8 weeks
|
Glucose level was measured every 2 weeks.
|
8 weeks
|
|
prolactin level
Time Frame: 8 weeks
|
Prolactin level was assessed every 2 weeks.
|
8 weeks
|
|
Insulin level
Time Frame: 8 weeks
|
insulin level was measured every 2 weeks
|
8 weeks
|
|
low-density lipoprotein cholesterol (LDL-C) level
Time Frame: 8 weeks
|
LDL-C level was measured every 2 weeks
|
8 weeks
|
|
high-density lipoprotein cholesterol (HDL-C) level
Time Frame: 8 weeks
|
HDL-C level was measured every 2 weeks
|
8 weeks
|
|
cholesterol level
Time Frame: 8 weeks
|
cholesterol level was measured every 2 weeks
|
8 weeks
|
|
triglycerides level
Time Frame: 8 weeks
|
triglycerides level was measured every 2 weeks
|
8 weeks
|
|
leptin level
Time Frame: 8 weeks
|
leptin level was measured every 2 weeks
|
8 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical Global Impression scale
Time Frame: 8 weeks
|
The clinical global impression scale was applied every 2 weeks.
The clinical global impression scale is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment.
The clinical global impression scale is rated from 0 (normal, not at all ill) to 7 (Among the most extremely ill patients).
|
8 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Mong-Liang Lu, MD, Taipei Meidcal University-Wan Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Endocrine System Diseases
- Schizophrenia Spectrum and Other Psychotic Disorders
- Hypothalamic Diseases
- Hyperpituitarism
- Pituitary Diseases
- Schizophrenia
- Hyperprolactinemia
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Metformin
Other Study ID Numbers
Other Study ID Numbers
- 98107
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.